Imaging probes for non-invasive tumoral detection and functional monitoring of cancer multidrug resistance

Abstract

Aim: Several cationic radiotracers originally developed as myocardial perfusion agents have shown potential for both early detection of cancer and non-invasive monitoring of multiple drug resistance (MDR) by single photon emission computed tomography. We have introduced two cationic complexes, ^99mTc-DMEOP [di-methoxy-tris-pyrazolyl-^99mTc-(CO)₃] and ^99mTc-TMEOP [tri-methoxy-tris-pyrazolyl-^99mTc-(CO)₃], which showed excellent preclinical results as cardiac imaging probes, namely a persistent heart uptake with rapid blood and liver clearance. This study aimed at the evaluation of their usefulness for tumoral detection and functional assessment of MDR.

Methods: The uptake and efflux kinetics of ^99mTc-DMEOP and ^99mTc-TMEOP were evaluated in human prostate, lung, and breast cancer cell lines, including drug-resistant cell lines that are known to overexpress the MDR P-glycoprotein (Pgp). The effects of MDR modulators were also studied. In vivo studies were performed in xenografted tumor models, and the MDR phenotype of the tumors was confirmed by Western blot.

Results: The uptake kinetics of both complexes in human cancer cell lines is comparable with the one found for ^99mTc-Sestamibi, increasing over time. The uptake of ^99mTc-TMEOP is greatly reduced in cells overexpressing Pgp and increased in the presence of a Pgp modulator. In nude mice, the tumor uptake of ^99mTc-TMEOP was higher in the MCF-7 xenografts compared with the MCF7 Pgp tumors.

Conclusion: The uptake kinetics of both complexes in human cancer cell lines is comparable with the one found for ^99mTc-Sestamibi, increasing over time. The uptake of ^99mTc-TMEOP is greatly reduced in cells overexpressing Pgp, and increased in the presence of a Pgp modulator. In nude mice, the tumor uptake of ^99mTc-TMEOP was higher in the MCF-7 xenografts compared with the MCF7 Pgp tumors.

Keywords

Noninvasive imaging / imaging probes / tumoral detection / multiple drug resistance / P-glycoprotein

References

[1] World Health Organization. Fact sheet 39- All cancers. 2018. Available from https://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet.pdf. [Last accessed on 15Feb 2020]

[2] Gottesman MM.Biochemistry of multidrug resistance mediated by the multidrug transporter..Annu Rev Biochem1993;62:385-427

[3] Gottesman MM.Mechanisms of cancer drug resistance..Annu Rev Med2002;53:615-27

[4] Coley HM.Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer..Cancer Treat Rev2008;34:378-90

[5] Sharma V.Monitoring multidrug resistance P-glycoprotein drug transport activity with single-photon emission computed tomography and positron emission tomography radiopharmaceuticals in: contrast agents IIIRadiopharmaceuticals - from diagnostics to therapeutics..Top Curr Chem2005;155-78

[6] Mohan HK.Cost-effectiveness of 99mTc-sestamibi in predicting response to chemotherapy in patients with lung cancer: systematic review and meta-analysis..J Nucl Med2009;50:376-81

[7] Kannan P,Zoghbi SS,Gottesman MM.Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications..Clin Pharmacol Ther2009;86:368-77 PMCID:PMC2746858

[8] Mendes F,Santos I.Metalloprobes for functional monitoring of tumor multidrug resistance by nuclear imaging..Dalton Trans2011;40:5377-93

[9] Piwnica-Worms D,Budding M,Kramer RA.Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex..Cancer Res1993;53:977-84

[10] Ballinger JR,Boxen I,Hartman NG.Technetium-99m-tetrofosmin as a substrate for P-glycoprotein: in vitro studies in multidrug-resistant breast tumor cells..J Nucl Med1996;37:1578-82

[11] Ballinger JR,Moore MJ.Technetium-99m-furifosmin as an agent for functional imaging of multidrug resistance in tumors..J Nucl Med1997;38:1915-9

[12] Rao VV,Kronauge JF.A novel areneisonitrile Tc complex inhibits the transport activity of MDR P-glycoprotein..Nucl Med Biol1998;25:225-32

[13] Bolzati C,Gandin V,Morellato N.(99m)Tc(N)-DBODC(5), a potential radiolabeled probe for SPECT of multidrug resistance: in vitro study..J Biol Inor Chem2013;18:523-38

[14] Chen S,Li X,Lu J.The evaluations of ^99mTc cyclopentadienyl tricarbonyl triphenyl phosphonium cation for multidrug resistance..Bioorg Med Chem Lett2017;27:3551-4

[15] Schillaci O,Madeddu G.[99mTc]sestamibi and [99mTc]tetrofosmin in oncology: SPET and fusion imaging in lung cancer, malignant lymphomas and brain tumors..Q J Nucl Med Mol Imaging2005;49:133-44

[16] Wang XS,Liu XL,Hu CS.The role of technetium-99m methoxyisobutyl isonitrile scintigraphy in predicting the therapeutic effect of chemotherapy against nasopharyngeal carcinoma..Cancer2011;117:2435-41

[17] Saggiorato E,Rosas R,Finessi M.99mTc-MIBI Imaging in the presurgical characterization of thyroid follicular neoplasms: relationship to multidrug resistance protein expression..J Nucl Med2009;50:1785-93

[18] Duan XY,Liu M.Technetium-99m-hexakis-2-methoxyisobutylisonitrile scintigraphy and multidrug resistance-related protein expression in human primary lung cancer..Ann Nucl Med2008;22:49-55

[19] Mubashar M,Chaudhary KS,Stamp GW.99mTc-sestamibi imaging in the assessment of toremifene as a modulator of multidrug resistance in patients with breast cancer..J Nucl Med2002;43:519-25

[20] Takamura Y,Taguchi T.Prediction of chemotherapeutic response by Technetium 99m--MIBI scintigraphy in breast carcinoma patients..Cancer2001;92:232-9

[21] Kurata S,Kawahara A,Kawano K.Assessment of 99mTc-MIBI SPECT(/CT) to monitor multidrug resistance-related proteins and apoptosis-related proteins in patients with ovarian cancer: a preliminary study..Ann Nucl Med2015;29:643-9

[22] Gomes CM,Que I,van der Pluijmet G.Functional imaging of multidrug resistance in an orthotopic model of osteosarcoma using 99mTc-sestamibi..Eur J Nucl Med Mol Imaging2007;34:1793-803

[23] Rowe SP,Solnes LB,Choudhary A.Correlation of ^99mTc-sestamibi uptake in renal masses with mitochondrial content and multi-drug resistance pump expression..EJNMMI Res2017;7:80 PMCID:PMC5624857

[24] Liu S,Zhai S,Hou G.Evaluation of (64)Cu(DO3A-xy-TPEP) as a potential PET radiotracer for monitoring tumor multidrug resistance..Bioconjug Chem2009;20:790-8 PMCID:PMC2710240

[25] Maria L,Videira M,Paulo A.Rhenium and technetium tricarbonyl complexes anchored by pyrazole-based tripods: novel lead structures for the design of myocardial imaging agents..Dalton Trans2007;3010-9

[26] Maria L,Garcia R,Paulo A.Tris(pyrazolyl)methane 99mtc tricarbonyl complexes for myocardial imaging..Dalton Trans2009;603-6

[27] Mendes F,Fernandes C,Santos I.Studies of the myocardial uptake and excretion mechanisms of a novel 99mTc heart perfusion agent..Nucl Med Biol2011;39:209-13

[28] Goethals LR,Caveliers V,De Geeter F.Rapid hepatic clearance of 99mTc-TMEOP: a new candidate for myocardial perfusion imaging..Contrast Media Mol Imaging2011;6:178-88

[29] Bolzati C,Boschi A,Duatti A.Synthesis of a novel class of nitrido Tc-99m radiopharmaceuticals with phosphino-thiol ligands showing transient heart uptake..Nucl Med Biol2000;27:369-74

[30] Modica-Napolitano JS.Basis for the selective cytotoxicity of rhodamine 123..Cancer Res1987;47:4361-5

[31] Bonnet S,Allalunis-Turner J,Beaulieu C.A mitochondria-K⁺ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth..Cancer Cell2007;11:37-51

[32] Pancrazio JJ,Kim YI.Voltage-activated K⁺ conductance and cell proliferation in small-cell lung cancer..Anticancer Res1993;13:1231-4

[33] Wonderlin WF,Strobl JS.Changes in membrane potential during the progression of MCF-7 human mammary tumor cells through the cell cycle..J Cell Physiol1995;165:177-85

[34] Reed PW.Ionophores..Methods Enzymol1979;55:435-54

[35] Hanstein WG.Uncoupling of oxidative phosphorylation..Biochim Biophys Acta1976;456:129-48

[36] Germano G,Kiat H,Berman DS.A quantitative phantom analysis of artifacts due to hepatic activity in technetium-99m myocardial perfusion SPECT studies..J Nucl Med1994;35:356-9

[37] Kailasnath P.Technetium-99m-labeled myocardial perfusion agents: are they better than thallium-201?.Cardiol Rev2001;9:160-72

[38] Kapur A,Davies G,Eastick S.A comparison of three radionuclide myocardial perfusion tracers in clinical practice: the ROBUST study..Eur J Nucl Med Mol Imaging2002;29:1608-16

[39] Llaurado JG.The quest for the perfect myocardial perfusion indicator...still a long way to go..J Nucl Med2001;42:282-4

[40] Parker JA.Cardiac nuclear medicine in monitoring patients with coronary heart disease..Semin Nucl Med2001;31:223-37

[41] Kim YS,Hsieh WY.Impact of bidentate chelators on lipophilicity, stability, and biodistribution characteristics of cationic 99mTc-nitrido complexes..Bioconjug Chem2007;18:929-36 PMCID:PMC2518965